Drugs / QLG1080
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06837896 | Feb 2025 → Nov 2026 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLG1080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06837896 ↗ |
| Route | Oral | “Oral administration” NCT06837896 ↗ |